ABT-202
| |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
Chemical and physical data | |
Formula | C9H13N3 |
Molar mass | 163.219 |
3D model (JSmol) | |
| |
| |
|
ABT-202 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors and has been researched for use as an analgesic, although it has not passed clinical trials.[1][2][3]
References
- ↑ Jain, K. K. (2004). "Modulators of nicotinic acetylcholine receptors as analgesics". Current Opinion in Investigational Drugs. 5 (1): 76–81. PMID 14983978.
- ↑ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.
- ↑ Xu, Naxing; Kim, Grace E.; Gregg, Hope; Wagdy, Azza; Swaine, Brendan A.; Chang, Min S.; El-Shourbagy, Tawakol A. (September 2004). "Automated 96-well liquid–liquid back extraction liquid chromatography–tandem mass spectrometry method for the determination of ABT-202 in human plasma". Journal of Pharmaceutical and Biomedical Analysis. 36 (1): 189–195. doi:10.1016/j.jpba.2004.05.013.
nAChRs |
| ||||
---|---|---|---|---|---|
Precursors (and prodrugs) | |||||
See also: Receptor/signaling modulators • Muscarinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators |
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.